ArticleIJTLD open2026
Integrated treatment-decision algorithms for childhood TB: modelling diagnostic performance and costs.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
backgroundTo improve childhood TB diagnosis, treatment-decision algorithms (TDAs) with and without chest X-ray (CXR) were developed for children under age 10. We aimed to model diagnostic performance and costs of implementing TDAs in primary health centre (PHC) and district hospital (DH) settings in Uganda.
methodsWe developed decision-tree models following the TDA pathway from evaluation to treatment-decision. We compared six scenarios with combinations of diagnostic testing (stool and respiratory Xpert, urine lipoarabinomannan, and/or CXR) at PHCs and DHs. Outcomes were diagnostic accuracy and cost per correct treatment-decision for a cohort of 10,000 children with presumptive TB using a Monte Carlo simulation from a health system perspective. Costs were reported in 2024 international dollars (I$).
resultsIn all scenarios, TDAs had high sensitivity (80.8%-91.9%) but low specificity (50.9%-60.9%). Total diagnostic and treatment costs for the cohort were I$1,768,958-2,470,298, largely driven by overtreatment of false-positive cases. Diagnostic costs were mostly offset by reducing overtreatment. The cost per treatment-decision was lowest using mobile CXR at PHCs (I$287) and highest with DH referral (I$449).
conclusionThe TDAs have high sensitivity and can be implemented at PHCs with lower costs than DHs. Improving specificity and reducing treatment costs would enable affordable, large-scale implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.